Zhang, JE ORCID: 0000-0003-1813-2207, Klein, Kathrin, Jorgensen, Andrea L
ORCID: 0000-0002-6977-9337, Francis, Ben
ORCID: 0000-0002-2130-5976, Alfirevic, Ana
ORCID: 0000-0002-2801-9817, Bourgeois, Stephane, Deloukas, Panagiotis, Zanger, Ulrich M and Pirmohamed, Munir
ORCID: 0000-0002-7534-7266
(2017)
Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response.
FRONTIERS IN PHARMACOLOGY, 8 (MAY).
323-.
![]() |
Text
Warfarin_CYP4F_Manuscript_Frontiers_Accepted_Version.pdf - Author Accepted Manuscript Download (453kB) |
![]() |
Text
Warfarin_CYP4F_Figures_Frontiers_Accepted_Version.pdf - Author Accepted Manuscript Download (961kB) |
![]() |
Text
Warfarin_CYP4F_Supplementary_Frontiers_Accepted_Version.pdf - Author Accepted Manuscript Download (924kB) |
Abstract
Genetic polymorphisms in the gene encoding cytochrome P450 (CYP) 4F2, a vitamin K oxidase, affect stable warfarin dose requirements and time to therapeutic INR. <i>CYP4F2</i> is part of the <i>CYP4F</i> gene cluster, which is highly polymorphic and exhibits a high degree of linkage disequilibrium, making it difficult to define causal variants. Our objective was to examine the effect of genetic variability in the <i>CYP4F</i> gene cluster on expression of the individual <i>CYP4F</i> genes and warfarin response. mRNA levels of the <i>CYP4F</i> gene cluster were quantified in human liver samples (<i>n</i> = 149) obtained from a well-characterized liver bank and fine mapping of the <i>CYP4F</i> gene cluster encompassing <i>CYP4F2</i>, <i>CYP4F11</i>, and <i>CYP4F12</i> was performed. Genome-wide association study (GWAS) data from a prospective cohort of warfarin-treated patients (<i>n</i> = 711) was also analyzed for genetic variations across the <i>CYP4F</i> gene cluster. In addition, SNP-gene expression in human liver tissues and interactions between <i>CYP4F</i> genes were explored <i>in silico</i> using publicly available data repositories. We found that SNPs in <i>CYP4F2</i>, <i>CYP4F11</i>, and <i>CYP4F12</i> were associated with mRNA expression in the <i>CYP4F</i> gene cluster. In particular, <i>CYP4F2</i> rs2108622 was associated with increased <i>CYP4F2</i> expression while <i>CYP4F11</i> rs1060467 was associated with decreased <i>CYP4F2</i> expression. Interestingly, these <i>CYP4F2</i> and <i>CYP4F11</i> SNPs showed similar effects with warfarin stable dose where <i>CYP4F11</i> rs1060467 was associated with a reduction in daily warfarin dose requirement (∼1 mg/day, <i>P<sub>c</sub></i> = 0.017), an effect opposite to that previously reported with <i>CYP4F2</i> (rs2108622). However, inclusion of either or both of these SNPs in a pharmacogenetic algorithm consisting of age, body mass index (BMI), gender, baseline clotting factor II level, <i>CYP2C9<sup>∗</sup>2</i> rs1799853, <i>CYP2C9<sup>∗</sup>3</i> rs1057910, and <i>VKORC1</i> rs9923231 improved warfarin dose variability only by 0.5-0.7% with an improvement in dose prediction accuracy of ∼1-2%. Although there is complex regulation across the <i>CYP4F</i> gene cluster, the opposing effects between the two SNPs in the <i>CYP4F</i> gene cluster appear to compensate for each other and their effect on warfarin dose requirement is unlikely to be clinically significant.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | warfarin, pharmacogenetics, mRNA expression, CYP4F2, CYP4F11, CYP4F12 |
Depositing User: | Symplectic Admin |
Date Deposited: | 12 Jun 2017 15:21 |
Last Modified: | 19 Jan 2023 07:03 |
DOI: | 10.3389/fphar.2017.00323 |
Open Access URL: | http://journal.frontiersin.org/article/10.3389/fph... |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3007834 |